1.12
price up icon2.75%   0.03
after-market アフターアワーズ: 1.11 -0.01 -0.89%
loading
前日終値:
$1.09
開ける:
$1.07
24時間の取引高:
8.08M
Relative Volume:
2.67
時価総額:
$124.14M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.6788
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
-21.13%
1か月 パフォーマンス:
-13.85%
6か月 パフォーマンス:
-68.09%
1年 パフォーマンス:
-84.31%
1日の値動き範囲:
Value
$1.00
$1.14
1週間の範囲:
Value
$1.00
$1.43
52週間の値動き範囲:
Value
$1.00
$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1189)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

FATE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.12 124.14M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
479.79 121.85B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
698.74 76.83B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
624.67 37.96B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.75 30.69B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
271.80 29.71B 3.32B -860.46M -1.04B -8.32

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
01:00 AM

NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.

01:00 AM
pulisher
Feb 22, 2025

Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World

Feb 20, 2025
pulisher
Feb 20, 2025

Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 18, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Feb 18, 2025
pulisher
Feb 18, 2025

Q1 Earnings Estimate for FATE Issued By Leerink Partnrs - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know - Yahoo Finance

Feb 17, 2025
pulisher
Feb 17, 2025

Fate Therapeutics (FATE) Projected to Post Quarterly Earnings on Monday - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

FY2024 Earnings Forecast for FATE Issued By Leerink Partnrs - Defense World

Feb 17, 2025
pulisher
Feb 16, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Fate Therapeutics, Inc. (FATE) Investors to Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys - accessnewswire.com

Feb 16, 2025
pulisher
Feb 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of “Hold” from Analysts - Defense World

Feb 16, 2025
pulisher
Feb 15, 2025

What is Leerink Partnrs’ Estimate for FATE Q1 Earnings? - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Feb 14, 2025
pulisher
Feb 14, 2025

SG Americas Securities LLC Acquires 10,511 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Feb 14, 2025
pulisher
Feb 10, 2025

Navigating FATE Stock: Fate Therapeutics Inc Journey - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Analysts review Fate Therapeutics Inc’s rating - Knox Daily

Feb 10, 2025
pulisher
Feb 06, 2025

CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail

Feb 06, 2025
pulisher
Feb 06, 2025

Take off with Fate Therapeutics Inc (FATE): Get ready for trading - SETE News

Feb 06, 2025
pulisher
Feb 06, 2025

Fate Therapeutics Inc (FATE) Stock: A Year of Market Movement, Down and Up - The InvestChronicle

Feb 06, 2025
pulisher
Feb 04, 2025

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap (FATE) - Seeking Alpha

Feb 04, 2025
pulisher
Feb 04, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

Fate Therapeutics Inc [FATE] Investment Appeal on the Rise - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate - Yahoo Finance

Feb 04, 2025
pulisher
Feb 04, 2025

Fate Therapeutics Inc (FATE)’s stock performance: a year in review - US Post News

Feb 04, 2025
pulisher
Feb 03, 2025

FATE 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys Before Mar. 22nd Deadline in Securities Class Action - ACCESS Newswire

Feb 03, 2025
pulisher
Feb 03, 2025

Fate Therapeutics Inc (FATE)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Feb 03, 2025
pulisher
Jan 31, 2025

Fate Therapeutics' SWOT analysis: stock poised for catalysts amid clinical progress - MSN

Jan 31, 2025
pulisher
Jan 28, 2025

Fate Therapeutics Inc (NASDAQ: FATE) Is A Buzzing Hot Stock - Stocks Register

Jan 28, 2025
pulisher
Jan 25, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Assenagon Asset Management S.A. - Defense World

Jan 25, 2025
pulisher
Jan 23, 2025

Equities Analysts Offer Predictions for FATE FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Research Analysts Set Expectations for FATE FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Jan 22, 2025
pulisher
Jan 19, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Update - MarketBeat

Jan 19, 2025
pulisher
Jan 16, 2025

JPMorgan Chase & Co. Has $6.43 Million Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 16, 2025
pulisher
Jan 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Bought by JPMorgan Chase & Co. - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

Day 0 of Loss Streak for Fate Therapeutics Stock with 0% Return (vs. -20% YTD) [1/22/2025] - Trefis

Jan 15, 2025
pulisher
Jan 14, 2025

Fate Therapeutics' SWOT analysis: stock poised for growth amid clinical progress - Investing.com

Jan 14, 2025
pulisher
Jan 13, 2025

Fate Therapeutics’ chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Nigeria

Jan 13, 2025
pulisher
Jan 13, 2025

Fate Therapeutics CEO sells shares worth $13,405 By Investing.com - Investing.com Canada

Jan 13, 2025
pulisher
Jan 13, 2025

Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 13, 2025

Fate Therapeutics executive sells $9,269 in common stock By Investing.com - Investing.com Canada

Jan 13, 2025
pulisher
Jan 13, 2025

Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Canada

Jan 13, 2025
pulisher
Jan 13, 2025

Insider Selling: Fate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $13,405.70 in Stock - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Barclays PLC Has $1.49 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 13, 2025
pulisher
Jan 07, 2025

Fate Therapeutics, Inc. Announces Retirement of J. Scott Wolchko as Treasurer, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer - Marketscreener.com

Jan 07, 2025
pulisher
Jan 07, 2025

Fate Therapeutics appoints new CEO, enters advisory pact By Investing.com - Investing.com Canada

Jan 07, 2025
pulisher
Jan 06, 2025

Fate Therapeutics appoints new CEO, enters advisory pact - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Fate Therapeutics Announces Executive Leadership Transition - TipRanks

Jan 06, 2025

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Fate Therapeutics Inc (FATE) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
TAHL CINDY
See Remarks
Jan 10 '25
Sale
1.55
5,654
8,764
336,707
Valamehr Bahram
President and CEO
Jan 10 '25
Sale
1.54
8,705
13,406
349,364
$81.55
price up icon 2.95%
$22.68
price down icon 0.31%
$33.64
price up icon 0.63%
$319.86
price down icon 1.18%
$113.03
price up icon 3.89%
biotechnology ONC
$271.80
price down icon 2.56%
大文字化:     |  ボリューム (24 時間):